Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I booster study of KD-414 after prior Pfizer or Moderna COVID-19 vaccination
jRCT1031210517Phase 1Active, not recruiting
- Sponsor
- Koga Michiko
- Start
- Dec 2021
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of KD-414 in coronavirus disease 2019 (COVID-19) (8 arms), sponsored by Koga Michiko. Primary endpoint: Exploratory immunogenicity. Started Dec 2021; status: active, not recruiting.
02
Drugs
KD-414
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT1031210517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210517.